Iteos Therapeutics Announces Delisting from Nasdaq Following Merger Completion
I'm PortAI, I can summarize articles.
Iteos Therapeutics Inc. has announced its delisting from Nasdaq following its merger with Concentra Biosciences, LLC. The company has completed a tender offer and is now a wholly owned subsidiary of Concentra. Trading of its shares will be suspended effective August 29, 2025, and Iteos intends to deregister its shares under the Securities Exchange Act of 1934. This marks a significant regulatory change in the company's public status post-merger.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments